Nerea Jauregizar
Overview
Explore the profile of Nerea Jauregizar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carton J, de-la-Fuente I, Sevillano E, Jauregizar N, Quindos G, Eraso E, et al.
J Fungi (Basel)
. 2025 Feb;
11(2).
PMID: 39997427
Invasive candidiasis is a common fungal infection associated with multiple risk factors, such as cancer, neutropenia, corticosteroid therapy, catheterization, and the use of broad-spectrum antibiotic treatment. is the predominant causative...
2.
Ramirez G, Campanero M, Zaldua A, Jauregizar N
Med Devices (Auckl)
. 2024 Oct;
17:349-367.
PMID: 39469419
Objective: The purpose of the current review is to identify the main problems of endotracheal intubation, which will serve as a basis for the design requirements for a novel endotracheal...
3.
Hernando-Ortiz A, Eraso E, Jauregizar N, de Groot P, Quindos G, Mateo E
Microbiol Spectr
. 2023 Nov;
12(1):e0208623.
PMID: 38018978
Multidrug resistance is a rising problem among non- species, such as . This therapeutic problem has been very important during the COVID-19 pandemic. The World Health Organization has included in...
4.
de-la-Fuente I, Guridi A, Jauregizar N, Eraso E, Quindos G, Sevillano E
J Fungi (Basel)
. 2023 Jun;
9(6).
PMID: 37367584
is an emerging fungal pathogen responsible for hospital outbreaks of invasive candidiasis associated with high mortality. The treatment of these mycoses is a clinical challenge due to the high resistance...
5.
Carral N, Lukas J, Estrade O, Jauregizar N, Morillas H, Suarez E
Antibiotics (Basel)
. 2023 May;
12(5).
PMID: 37237741
The consequences of non-adherence to treatment (NAT) on antimicrobial efficacy may depend on drug forgiveness-a property that should account for pharmacokinetics (PK) and pharmacodynamics (PD) as well as interindividual variability....
6.
Caballero U, Eraso E, Quindos G, Vozmediano V, Schmidt S, Jauregizar N
CPT Pharmacometrics Syst Pharmacol
. 2023 Mar;
12(6):770-782.
PMID: 36915233
In vitro combination of echinocandins and isavuconazole against the emerging species Candida auris is mainly synergistic. However, this combination has not been evaluated in clinical settings. A pharmacokinetic/pharmacodynamic modeling and...
7.
Jauregizar N, Quindos G, Gil-Alonso S, Suarez E, Sevillano E, Eraso E
J Fungi (Basel)
. 2022 Jul;
8(7).
PMID: 35887482
The study of the pharmacological properties of an antifungal agent integrates the drug pharmacokinetics, the fungal growth inhibition, the fungicidal effect and the postantifungal activity, laying the basis to guide...
8.
Quindos G, Miranda-Cadena K, San-Millan R, Borroto-Esoda K, Canton E, Linares-Sicilia M, et al.
Front Cell Infect Microbiol
. 2022 Jun;
12:906563.
PMID: 35651755
Background: Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. Objective: The aim of this study was to assess...
9.
Caballero U, Eraso E, Peman J, Quindos G, Vozmediano V, Schmidt S, et al.
Pharmaceutics
. 2021 Nov;
13(11).
PMID: 34834182
The aims of this study were to characterize the antifungal activity of amphotericin B against in a static in vitro system and to evaluate different dosing schedules and MIC scenarios...
10.
Caballero U, Eraso E, Quindos G, Jauregizar N
Pharmaceutics
. 2021 Sep;
13(9).
PMID: 34575409
Treatment of invasive infections caused by is challenging due to the limited therapeutic options. The combination of antifungal drugs may be an interesting and feasible approach to be investigated. The...